Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
Status:
COMPLETED
Trial end date:
2025-08-20
Target enrollment:
Participant gender:
Summary
In this clinical study, the safety and tolerability of HER-096 and the way the body interacts with the drug (pharmacokinetics) will be investigated. The clinical study consists of two parts. In Part 1, the drug HER-096 is given as a single dose to healthy volunteer subjects. In Part 2, HER-096 or placebo (physiological saline) is given as multiple doses during a 4-week period to patients with Parkinsons disease. The doses are given as injections under the skin (subcutaneous injection).
Phase:
PHASE1
Details
Lead Sponsor:
Herantis Pharma Plc.
Collaborators:
BC Platforms Clinical Research Services Turku - CRST Ltd Oy Medfiles Ltd